

Werner's syndrome and acute myeloid leukemia

L. C. Tao, M.D., Ellyn Stecker, B.A. and
H. A. Gardner, M.D., M.Sc., D.C.P., D.PATH., C.R.C.P.[C], *Toronto*

Werner's syndrome was first described by Otto Werner¹ in 1904. He reported a family of two brothers and two sisters who had the appearance of premature ageing. Although only in their twenties, they had loss and greying of hair, cataracts and pinched facial features. In addition there were "scleroderma-like" skin changes of their feet. Since Werner's original report, 136 such cases have been recorded in the literature.²⁻⁵ Most patients have been of European, Jewish or Japanese ancestry.

Most of the major clinical manifestations of Werner's syndrome do not appear until the second and third decades, and the average age at death is 47 years.² The two principal causes of death are vascular accidents involving the coronary and cerebral arteries, and malignancy. Malignancy occurred in 14 of the 136 recorded patients. This incidence of about 10% suggests an increased susceptibility.

Our purpose in this paper is to describe the autopsy findings of a patient with this rare disease who developed acute myeloid leukemia as a terminal event. Tissue culture and cytogenetic studies were also performed.

Case history

Our patient (M.P.) was a white woman born in 1945 who died at 24 years of age. Aside from the usual illnesses she was in good health throughout her childhood. She completed grade nine in school and worked in a hospital as a nurses' aide. In 1965, at 20 years of age, she underwent removal of both lenses because of cataracts, at Women's College Hospital, Toronto. During this admission she was discovered to be mildly diabetic with a slightly raised systolic blood pressure (140-150 mm. Hg). Further investigation of these problems had to be deferred because she became pregnant. A spontaneous abortion terminated the pregnancy at 19 weeks.

Nothing further was done until May 1968, when she was investigated at the

Toronto General Hospital. She was described as lean and emaciated, with "pinched" facies. There was evidence of muscle atrophy in all her extremities as well as a striking loss of subcutaneous tissue. Her blood pressure was 160/80. Mild diabetes was easily controlled by dietary measures. Her ESR was 65 mm. in the first hour. LE cells could not be demonstrated. Hematologic studies were normal. Although the working diagnosis was a collagen disorder, no conclusions were reached.

She was readmitted one year later, in April 1969. During the previous two weeks she had become short of breath on exertion, and within the preceding few days she had had recurrent nose bleeds, profuse vaginal bleeding and spontaneous bruising. Her hemoglobin was 5.5 g. per 100 ml. and the platelet count was 20,000 per c.mm. Her total leukocyte count was 9700 with 17% neutrophils, 6% lymphocytes, 9% metamyelocytes, 28% myelocytes, 25% promyelocytes and 10% blasts. Two bone marrow aspirations were unsuccessful, and a posterior iliac crest bone biopsy was performed; this showed an extremely hypercellular marrow with a marked increase in primitive cells, establishing a diagnosis of acute leukemia. She was treated with blood transfusion, prednisone (which induced a remission), and a cyclic estrogen-progesterone preparation (which controlled her vaginal bleeding).

It was during this admission that the diagnosis of Werner's syndrome was recognized. The marked alteration of facial

features which had occurred between 1964 and 1969 can be seen in Figs. 1a and 1b.

Her last admission to Toronto General Hospital on October 17, 1969, was necessitated by recurrent epistaxis, vaginal bleeding, and ulcers on her left leg and in the perineal region. Uterine curettage was performed to control her vaginal bleeding, and examination of the endometrium showed leukemic infiltrate of the myeloid series. Blast cells in her peripheral blood rose to 40%. 6-Mercaptopurine and vincristine had no effect on her course and she died on November 13, 1969.

Family history

The parents of M.P. were second cousins once removed (Fig. 2). The family is large and includes four paternal uncles, four paternal first cousins, eight maternal uncles, one maternal aunt and 16 maternal first cousins. No other member of the patient's family has Werner's syndrome. One maternal uncle has diabetes. Both the father and the brother of the patient had thinning of the hair at an early age. Neither premature greying of the hair nor cataracts were present in other members of the family.

Autopsy findings

The patient was 157 cm. tall and weighed 41 kg. She appeared older than her stated age, with a sharp pinched facies, parchment-like skin and subcutaneous and muscle atrophy of her extremities. Cutaneous ulcers were present on her legs and perineum. There was relatively good preservation of abdominal fat. Her scalp hair was not grey nor was there baldness.

The bone marrow was packed with leukemic cells. Their nuclei had fine chromatin and contained two to six nucleoli. Some cells exhibited a fine paranuclear granularity. These features are compatible with primitive cells of the myeloid series. The spleen (Fig. 3), lymph nodes, liver, lungs, kidneys, uterus and skin all showed leukemic involvement.



FIG. 1—(a) The natural appearance of the patient in 1964 is contrasted with (b) the "Werner's" appearance in 1969. The thin, "pinched" facial features of Werner's syndrome are well demonstrated.

New Valisone Scalp Lotion.

DESCRIPTION:

Each gram of VALISONE Scalp Lotion contains 1.0 mg (0.1%) betamethasone (as valerate N.F.) in an aqueous, alcohol base.

INDICATIONS:

VALISONE Scalp Lotion is especially indicated in the management of dermatoses of the scalp but may be used in any corticosteroid-responsive dermatoses, such as: atopic eczema, infantile eczema, nummular eczema, anogenital and senile pruritus, contact dermatitis, seborrheic dermatitis, neurodermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, and psoriasis. Refractory psoriasis may be successfully treated with VALISONE Scalp Lotion in conjunction with the hydration technique.

In allergic or contact dermatitis, VALISONE Scalp Lotion provides excellent symptomatic relief.

DOSAGE:

A small amount applied two to three times daily on the affected skin.

PRECAUTIONS AND CONTRAINDICATIONS:

Betamethasone valerate preparations should not be used on patients with tuberculosis of the skin, chickenpox, herpes simplex, and vaccinia. Application in or near the eyes should be avoided. Corticosteroids are known to be absorbed percutaneously and in patients under prolonged occlusive treatment, the possibility of metabolic effects should be kept in mind.

Further detailed information on betamethasone valerate is available from Schering Corporation Limited, Pointe Claire 730, Quebec (and is also published in the *Compendium of Pharmaceuticals and Specialties, 1971*, under Celestoderm*-V).

Atherosclerosis was present in all major arteries, but except in the coronary arteries the changes were mild, being manifested by fatty streaks. The coronary arteries showed areas of pronounced plaque formation.

Sections of skin taken from the leg showed flattening of the rete ridges and fibrous replacement of the dermis. The number of hair follicles and other appendages were decreased. The adrenal gland showed hyperplasia of the zona glomerulosa. Sections of ovary showed a corpus luteum, a few corpora albicantes and a number of primary follicles. No developing follicles were present.

The brain weighed 1120 g.—slightly less than a normal brain at this age. There were no pathologic abnormalities to be seen. The basophils of the pituitary showed Crooke's hyaline change, the result of prednisone therapy.

Cytogenetic and tissue culture studies

Chromosome analyses were performed on several occasions. All cultures were grown in Media TC 199 (Hyland) supplemented with 20% fetal calf serum, penicillin and streptomycin, heparin and phytohemagglutinin (PHA).

On April 25, 1969, 10 cells from a peripheral blood culture were examined at The Hospital for Sick Children, Toronto, and two karyotypes were made. On June 10, 1969, peripheral blood was cultured at Toronto General Hospital. Ten cells in metaphase were analyzed. At autopsy on October 24, 1969, blood was taken and leukocyte-rich plasma was cultured. Twenty-eight cells were analyzed and two karyotypes were made. Thus a total of 48 cells from peripheral blood were examined. The basic chromosome pattern was that of a normal woman, 46, XX. Other cultures incubated without PHA also had a 46,XX pattern, and no chromosome abnormalities related to the acute leukemia were found.

Fiver coverslip cultures in Leighton tubes were prepared from skin taken at autopsy three hours after death. The lag period preceding the beginning of growth was very long—30 days. Following this there was a slow but definite proliferative phase, so that enough cells were present by day 55 for subculturing. Although the cells settled and seemed to adhere well to the new coverslips, growth was poor, and by day 90 the three subcultures were degenerating. Attempts to obtain metaphase preparations for chromosome studies were unsuccessful.

At the time these skin cultures were initiated it was not possible to set up a matched control. The cultural characteristics were therefore compared with those of other autopsy and biopsy skin fibroblast preparations initiated during this same period of time, handled in the same manner and using the same media. These cultures had evident growth within five to 10 days, subcultures being possible at 10- to 14-day intervals for many months.

Discussion

Werner's syndrome and premature ageing have many features in common and have frequently been confused. Atherosclerosis, greying and loss of hair, and dermal and subcutaneous atrophy are present in both conditions. On the other hand there are features which are characteristic of Werner's syndrome and distinguish it from ageing.

The many family studies which have been reported seem to establish fairly certainly that Werner's syndrome is inherited in an autosomal recessive manner. Although this illness does occur sporadically, many patients are the products of consan-




FIG. 2—Abridged pedigree of M.P. The patient's parents were second cousins once removed.




FIG. 3—Microphotograph of spleen illustrating infiltration by primitive myeloid cells (H. & E., X600.)

guineous marriages,⁶⁻¹² as was true of our patient.

It has been suggested that in the family of a patient who has Werner's syndrome, diabetes or early thinning of the hair with or without premature greying represents a variant of this illness or its heterozygous state.^{2, 3} We find it difficult to come to this conclusion. Diabetes was present in one uncle of the patient. However, diabetes itself is a familial disease and is common in the community. The same is true of premature balding (present in the father and brother) and greying. We therefore cannot establish these traits as indicative of a variant or the heterozygous state of Werner's syndrome.

The early and abrupt appearance of cataracts, as occurred in our patient, is characteristic of Werner's syndrome. Cataracts usually appear before the age of 40 and begin as homogeneous or striate opacities in the subcapsular, cortical and posterior zones of the lens.¹³ The cataracts of normal ageing begin in the nuclear region of the lens.

Generalized and early atherosclerosis is reported as being prominent in Werner's syndrome.² Severe atheromatous changes were observed in our patient's coronary arteries but only fatty streaks were present in the other major vessels.

Hypogonadism and maturity-onset diabetes are common endocrine problems. Small breasts and ovaries were present in this patient but there was no evidence of oligomenorrhea or early menopause. The incidence of diabetes in Werner's syndrome is 45%. It is usually mild, but unresponsive to insulin. Our patient's diabetes was mild and diet proved effective in controlling it; insulin was not required. The zona glomerulosa of the adrenal gland is wider in Werner's syndrome than is found normally.² This was true in this patient.

The most salient clinical manifestation of Werner's syndrome is the subcutaneous atrophy, and this was well documented in our patient. Involvement of the face caused the skin to mould to the bony contours, giving her a thin, sharp, "pinched" appearance. The skin of the extremities was shiny, thin and parchment-like, and there were trophic ulcers on her legs. The underlying musculature was atrophic.

The finding of a normal chromosome complement in our patient

agrees with previous observations.^{2, 7, 13-18} Few reports describe the characteristics of cultured fibroblasts, but our observations are consistent with the one study which has been published.^{2, 19, 24} The fibroblasts are less efficient in establishing growing colonies than normal cells, and once established few subcultures can be undertaken before the culture degenerates.²⁴

The 136 patients with Werner's syndrome recorded in the literature show a high incidence of neoplastic disease. Fourteen cases with malignant tumours have been reported. Seven had a sarcoma: fibrosarcoma,^{3, 8} fibroliposarcoma,²⁰ osteogenic sarcoma,^{4, 7, 20} sarcoma of nerve sheath origin,⁷ leiomyosarcoma²¹ or spindle-cell sarcoma.²² Seven had a carcinoma: cholangiocarcinoma,¹² liver cell carcinoma,^{3, 8, 20} carcinoma of breast,⁹ papillary carcinoma of thyroid⁶ or malignant melanoma.¹⁰ Solitary meningiomas were found in two patients,^{12, 23} and multiple meningiomas in a third patient.³ Adenomas of the thyroid and adrenals were noted in several patients,² as well as a leiomyoma of the uterus in a 26-year-old woman.¹¹ One patient had a hemangiolipoma with occasional mitoses.¹⁴

Our patient appears to be the first case associated with leukemia. Neither the type of leukemia (acute myeloblastic), its course (seven months) nor the age of onset (24 years) seemed in any way affected by her Werner's syndrome.

We are very grateful to Dr. Diane W. Cox, Department of Genetics, The Hospital for Sick Children, Toronto, for her help in gathering a comprehensive family study on this patient and reviewing the manuscript. We also thank Dr. A. C. Ritchie and Dr. C. Ezrin for their comments and criticisms.

Summary:

A 24-year-old white woman with Werner's syndrome developed acute myelogenous leukemia. The autopsy findings are described. Tissue culture studies indicated abnormalities of *in vitro* fibroblast growth. Cytogenetic studies of peripheral blood lymphocytes revealed a normal female chromosome pattern of 46,XX. The disease is inherited as an autosomal recessive, but its pathogenesis is not known.

There is a relatively high incidence of neoplastic disease in patients with

Werner's syndrome. Fourteen of 136 cases recorded in the literature are associated with malignant tumours. This is the first recorded case in which leukemia developed.

References

1. WERNER O: Uber Katarakt in Verbindung mit Sklerodermie. (Doctoral dissertation, Kiel University), Kiel, Schmidt & Kleunig, 1904
2. EPSTEIN CJ, MARTIN GM, SCHULTZ AL, et al: Werner's syndrome. *Medicine (Baltimore)* 45: 177-221, 1966
3. ZUCKER-FRANKLIN D, RIFKIN H, JACOBSON HG: Werner's syndrome. An analysis of ten cases. *Geriatrics* 23: 123-135, 1968
4. ROSEN RS, CIMINI R, COBLENTZ D: Werner's syndrome. *Br J Radiol* 43: 193-198, 1970
5. THANNHAUSER SJ: Werner's syndrome (progeria of the adult) and Rothmund's syndrome: two types of closely related hereditary atrophic dermatoses with juvenile cataracts and endocrine features; a critical study with five new cases. *Ann Intern Med* 23: 559-626, 1945
6. VALERO A, GELLEI B: Retinitis pigmentosa, hypertension, and uraemia in Werner's syndrome. Report of a case with necropsy findings. *Br Med J* 2: 351-354, 1960
7. MCKUSICK VA: Medical genetics 1962. *J Chronic Dis* 16: 600, 1963
8. OPPENHEIMER BS, KUGEL VH: Werner's syndrome; report of first necropsy and of findings in new case. *Am J Med Sci* 202: 629-642, 1941
9. SCHOTT J, DANN S: Werner's syndrome. A report of two cases. *N Engl J Med* 240: 641-644, 1949
10. ELLISON DJ, PUGH DW: Werner's syndrome. *Br Med J* 2: 237-239, 1955
11. FIELD JB, LOUBE SD: Observations concerning the diabetes mellitus associated with Werner's syndrome. *Metabolism* 9: 118-124, 1960
12. ROGERS AS: Werner's syndrome. Report of case with unusual complication. *J Fla Med Assoc* 46: 436-438, 1959
13. PETROHELOS MA: Werner's syndrome. A survey of three cases, with review of the literature. *Am J Ophthalmol* 56: 941-953, 1963
14. ILLIS L: A case of Werner's syndrome. *Postgrad Med J* 38: 286-289, 1962
15. FRACCARO M, BOTT MG, CALVERT HT: Chromosomes in Werner's syndrome. *Lancet* i: 536, 1962
16. LEARNER N, DAY HJ, WEISS L, et al: Chromosomes in Werner's syndrome. *Ibid* p 536
17. MOTULSKY AG, SCHULTZ A, PRIEST J: Werner's syndrome. Chromosomes, genes, and the aging process. *Lancet* i: 160-161, 1962
18. COHEN M, SHELLEY WB: Ankle ulcer sign of Werner's syndrome. *Arch Dermatol* 87: 86-88, 1963
19. MARTIN GM, GARTLER SM, EPSTEIN CJ, et al: Diminished lifespan of cultures cells in Werner's syndrome. *Fed Proc* 24: 678, 1965
20. JACOBSON HG, RIFKIN H, ZUCKER-FRANKLIN D: Werner's syndrome. A clinical roentgenological entity. *Radiology* 74: 373-385, 1960
21. MULLER L, ANDERSSON B: Werner's syndrome. A survey based on two cases. *Acta Med Scand* (suppl 283): 3-17, 1953

Continued on page 968

- glucagon on phenylethanolamine-n-methyl transferase of rat adrenal. *Proc Soc Exp Biol Med* 127: 296-300, 1968
15. VANCE JE, BUCHANAN KD: Interrelationship between glucagon and insulin release from isolated islets of Langerhans. *Diabetes* 17 (Suppl 1): 311-312, 1968
 16. SALSBERG BB, YAKIMETS WW, CROCKFORD PM: Hypoglycemia and glucagon release. *Proc Can Fed Biol Soc* 11: 36, 1968
 17. BELL NH, KIMBLE JB: Effects of glucagon, dibutyl cyclic 3',5'-adenosine monophosphate and theophylline on calcitonin secretion in vitro. *J Clin Invest* 49: 1368-1373, 1970
 18. TASHJIAN AH, HOWLAND BG, MELVIN KEW, et al: Immunoassay of human calcitonin in normal and disease states. *N Engl J Med* 283: 890-895, 1970
 19. PALOYAN E, LAWRENCE AM, STRAUS FH, et al: Alpha cell hyperplasia in calcific pancreatitis associated with hyperparathyroidism. *JAMA* 200: 757-761, 1967
 20. OHNEDA A, AGUILAR-PARADA E, EISENTRAUT AM, et al: Control of pancreatic glucagon secretion by glucose. *Diabetes* 18: 1-10, 1969
 21. AGUILAR-PARADA E, EISENTRAUT AM, UNGER RH: Effects of starvation on plasma pancreatic glucagon in normal man. *Diabetes* 18: 717-723, 1969
 22. EDWARDS JC, HOWELL SL, TAYLOR KW: Effects of metabolic inhibitors on glucagon release from isolated guinea-pig islets of Langerhans. *Biochem J* 177: 32P-33P, 1970
 23. UNGER RH, OHNEDA A, AGUILAR-PARADA E, et al: The role of aminogenic glucagon secretion in blood glucose homeostasis. *J Clin Invest* 48: 810-822, 1969
 24. CHESNEY T, SCHOFIELD JG: Studies on the secretion of pancreatic glucagon. *Diabetes* 18: 627-632, 1969
 25. EDWARDS JC, HOWELL SL, TAYLOR KW: Fatty acids as regulators of glucagon secretion. *Nature* 224: 808-809, 1969
 26. MARKS V, SAMOLS E: Glucagon test for insulinoma: A chemical study in 25 cases. *J Clin Path* 21: 346-352, 1968
 27. MARKS V, ROSE FC: *Hypoglycemia*. Oxford Blackwell Scientific, 1965
 28. MARRI G, COZZOLINO G, PALUMBO R: Glucagon in sulphonylurea hypoglycemia. *Lancet* 1: 303-304, 1968
 29. CORNBATH M, SCHWARTZ R: *Disorders of Carbohydrate Metabolism in Infancy*. Philadelphia, Saunders, 1967, p 209
 30. LEFEBVRE PJ, CESSION-FOSSION A, LUYCKX AS: Glucagon test for pheochromocytoma. *Lancet* 2: 1366, 1966
 31. LAWRENCE AM: Radioimmunoassayable glucagon levels in man: Effects of starvation, hypoglycemia and glucose administration. *Proc Natl Acad Sci USA* 55: 316-320, 1966
 32. GLICK G, PARMLEY WW, WECHSLER AS, et al: Glucagon: Its enhancement of cardiac performance in cat and dog and persistence of its inotropic action despite beta receptor blockade with propranolol. *Circ Res* 22: 789-799, 1968
 33. NORD HJ, FONTANES AL, WILLIAMS JF: Treatment of congestive heart failure with glucagon. *Ann Intern Med* 72: 649-653, 1970
 34. MCQUARRIE I: Idiopathic spontaneously occurring hypoglycemia in infants. *Am J Dis Child* 87: 399-428, 1954
 35. GROLLMAN A, MCCAULEY WE, WHITE FN: Glucagon deficiency as a cause of hypoglycemia. *Metabolism* 13: 686-690, 1964
 36. BLEISH VR, MAYER J, DICKIE MM: Familial diabetes mellitus in mice, associated with insulin resistance, obesity and hyperplasia of the islets of Langerhans. *Am J Pathol* 28: 369-386, 1952
 37. PAULSON EP, LAWRENCE AM: Glucagon hypersecretion in obese children. *Lancet* 2: 110, 1968
 38. CROCKFORD PM, HAZZARD WR, WILLIAMS RH: Insulin response to glucagon: The opposing effects of diabetes and obesity. *Diabetes* 18: 216-224, 1969
 39. MULLER WA, FALOONA GR, AGUILAR-PARADA E, et al: Abnormal alpha-cell function in diabetes: Response to carbohydrate and protein. *New Engl J Med* 283: 109-115, 1970
 40. UNGER RH, AGUILAR-PARADA E, MULLER WA, et al: Studies of pancreatic alpha cell function in normal and diabetic subjects. *J Clin Invest* 49: 837-848, 1970
 41. SAMOLS E, TYLER JM, MIALHE P: Suppression of pancreatic glucagon release by the hypoglycemic sulphonylureas. *Lancet* 1: 174-176, 1969
 42. BUCHANAN KD, WILLIAMS RH, VANCE JE: Pancreatic glucagon release and sulphonylureas. *Ibid* 420-421
 43. MCGAVRAN MH, UNGER RH, RECENT L, et al: A glucagon-secreting alpha cell carcinoma of the pancreas. *N Engl J Med* 274: 1408-1413, 1966
 44. YOSHINAGA T, OKUNO G, SHINJI Y, et al: Pancreatic A-cell tumor associated with severe diabetes mellitus. *Diabetes* 15: 709-713, 1966
 45. O'NEAL LW, KIPNIS DM, LUSE SA, et al: Secretion of various endocrine substances by ACTH-secreting tumors—gastrin, melanotropin, norepinephrine, serotonin, parathormone, vasopression and glucagon. *Cancer* 21: 1219-1232, 1968
 46. VANCE JE, KITABCHI AE, BUCHANAN KD, et al: Hypersecretion of insulin, glucagon and gastrin in a kindred with multiple adenomatosis. *Diabetes* 17 (Suppl 1): 299, 1968
 47. UNGER RH, DE V LOCHNER J, EISENTRAUT AM: Identification of insulin and glucagon in a bronchogenic metastasis. *J Clin Endocrinol Metab* 24: 823-831, 1964
 48. MAKMAN MH, SUTHERLAND EW: Use of liver adenyl cyclase for assay of glucagon in human gastro-intestinal tract and pancreas. *Endocrinology* 75: 127-134, 1964
 49. SAMOLS E, TYLER J, MARRI G, et al: Stimulation of glucagon secretion by oral glucose. *Lancet* 2: 1257-1259, 1965
 50. BUCHANAN KD, VANCE JE, AOKI T, et al: Rise in serum immunoreactive glucagon after intrajeunal glucose in pancreatectomized dogs. *Proc Soc Exp Biol Med* 126: 813-815, 1967
 51. UNGER RH, OHNEDA A, VALVERDE I, et al: Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. *J Clin Invest* 47: 48-65, 1968
 52. VALVERDE I, RIGOPOULOS D, EXTON J, et al: Demonstration and characterization of a second fraction of glucagon-like immunoreactivity in jejunal extracts. *Am J Med Sci* 255: 415-420, 1968
 53. MARCO J, FALOONA GR, UNGER RH: Effect of gut glucagon-like immunoreactivity (GLI) on insulin secretion. *Diabetes* 19 (Suppl 1): 366-367, 1970
 54. SAMOLS E: Endogenous glucagon in man and animals. Unpublished presentation, American Diabetes Association Research Symposium on Glucagon, San Francisco, California, 1966
 55. REHFELD JR, HEDING LG: Increased release of gut glucagon in reactive hypoglycemia. *Br Med J* 2: 706-707, 1970

Werners syndrome

Continued from page 954

22. MATRAS A, KOHLER J: Ein Beitrag zum Werner-Syndrom. *Wien Med Wochenschr* 106: 437-441, 1956
23. MOGENSEN EF: *Ugeskr Laeg* 115: 18, 1953, cited by EPSTEIN CJ, MARTIN GM, SCHULTZ AL, et al: Werner's syndrome. *Medicine* 45: 177-222, 1966
24. EPSTEIN CJ, MARTIN GM, MOTULSKY AG: Werner's syndrome: caricature of aging. A genetic model for the study of degenerative diseases. *Trans Assoc Am Physicians* 68: 73-81, 1965

Functions

Continued from page 961

20. LOUBATIERE A: In the Structure and Metabolism of Pancreatic Islets, ed by Falkmer S, Hellman B and Taljedal IB, Pergamon Press, 1970, pp 450-451
21. FRERICH S, CREUTZFELDT C, CREUTZFELDT W: Inhibitors of insulin secretion. *Acta Diabetol Lat* 5: supplement 1, 105-123, 1968
22. SODOYEZ JC, SODOYEZ-GOFFAUX F, FOA PP: Feedback regulation insulin secretion by insulin: role of 3', 5'-cyclic AMP. In *the Structure and Metabolism of the Pancreatic Islets*, edited by Falkmer S, Hellman B and Taljedal IB, Pergamon Press, 1970, pp 445-451
23. HAIST RE: Effects of changes in stimulation on the structure and function of islet cells. Excerpta Medica International Congress Series No. 84: 12-30, 1965

Erratum

The review of the book "My Brother's Keeper?" by Dr. Monica C. Stewart (*Can Med Assoc J* 105: 411, 1971) mistakenly gives the impression that Dr. Lewis is the author of the second edition of this book. In the text of the review, the name Dr. Stewart should appear instead of Dr. Lewis. We regret the occurrence of this error.